Roche, Genentech: Tecentriq Meets Primary Endpoint in Interim Lung Cancer Trial

 Swiss drug major Roche Group (RHHBY) and its U.S. unit Genentech announced Monday positive results from Phase III IMpower010 study evaluating Tecentriq (atezolizumab) in people with early lung cancer.

According to the companies, Tecentriq in the trial met its primary endpoint of disease-free survival or DFS at the interim analysis in people with resectable early stage lung cancer compared to best supportive care or BSC.

Tecentriq showed a statistically significant improvement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer or NSCLC.

It is the first Phase III study that shows a cancer immunotherapy helped people with early lung cancer live longer without their disease returning.

https://www.nasdaq.com/articles/roche-genentech%3A-tecentriq-study-meets-primary-endpoint-at-interim-analysis-in-early-lung